ArticleNPJ biofilms and microbiomes2025
Garvicin Q-producing Lactococcus garvieae LG3092: its role in mitigating dysbiosis and H. pylori-associated gastritis.
Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunological, Inflammatory, and Microbiota Determinants of Carpal Tunnel Syndrome: Evidence from Mendelian Randomization.Endocrine, metabolic & immune disorders drug targets · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
H. pylori induces gastritis and promotes gastric carcinogenesis. Antimicrobial therapy against H. pylori often causes gastrointestinal dysbiosis, with side effects like vomiting, diarrhea, and antibiotic resistance, hindering effective eradication. This study investigated the effects and mechanisms of probiotics in balancing microbiota to alleviate H. pylori-related gastritis. Using in vivo and in vitro gastritis models with various H. pylori virulence strains, the study employed 16S rRNA amplicon sequencing and qPCR to link gastric microbiota with inflammation. Genomic mining and microbiota reconstruction identified Lactococcus garvieae LG3092 and GarQ as key microecological-targeting regulators. Results showed that different H. pylori induce varying levels of gastritis in vivo, with elevated IL-1β, IL-6, and TNF-α levels linked to pro-inflammatory bacteria. LG3092 secretes GarQ, specifically targeting Man-PTS receptors on pro-inflammatory bacteria, disrupting their membranes and modulating the gastric microbiota, highlighting the potential of probiotics in combination with other therapies to managing H. pylori infection and related gastritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.